Lars Hjorth
11 – 20 of 97
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Risk Factors for Primary Bone Cancer After Childhood Cancer : A PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies Nested Case-Control Study
2023) In Journal of clinical oncology : official journal of the American Society of Clinical Oncology 41(21). p.3735-3746(
- Contribution to journal › Article
-
Mark
Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023) In Clinical cancer research : an official journal of the American Association for Cancer Research 29(24). p.5057-5068(
- Contribution to journal › Article
- 2022
-
Mark
Male breast cancer after childhood cancer : Systematic review and analyses in the PanCareSurFup cohort
(
- Contribution to journal › Article
-
Mark
Impact of era of diagnosis on cause-specific late mortality among 77 423 five-year European survivors of childhood and adolescent cancer : The PanCareSurFup consortium
(
- Contribution to journal › Article
-
Mark
Childhood cancer survivorship care during the COVID-19 pandemic : an international report of practice implications and provider concerns
(
- Contribution to journal › Article
-
Mark
The PanCareFollowUp Care Intervention : A European harmonised approach to person-centred guideline-based survivorship care after childhood, adolescent and young adult cancer
(
- Contribution to journal › Article
-
Mark
Evaluating the feasibility, effectiveness and costs of implementing person-centred follow-up care for childhood cancer survivors in four European countries : the PanCareFollowUp Care prospective cohort study protocol
(
- Contribution to journal › Article
-
Mark
Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma
(
- Contribution to journal › Article
-
Mark
The chance of transition : strategies for multidisciplinary collaboration
(
- Contribution to journal › Scientific review
-
Mark
A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N
(
- Contribution to journal › Article